A study of efficacy and safety with apatinib therapy in advanced neuroendocrine carcinoma patients

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Neuroendocrine Tumours
Presenter Chao Chen
Citation Annals of Oncology (2018) 29 (suppl_9): ix113-ix120. 10.1093/annonc/mdy441
Authors C. Chen, X. Liu, C. Han
  • Department Of Medical Oncology Of Pla Cancer Center,, Bayi Hospital Affiliated Nanjing University of Chinese Medicine, 210002 - Nanjing/CN

Abstract

Background

There is no standard therapeutic method for advanced neuroendocrine carcinoma patients after second line chemotherapy. There is a need for novel effective therapies for these patients. Apatinib (Hengrui Pharmaceutical Co.,Ltd, Shanghai, People’s Republic of China) is a novel small molecular vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor, which is mainly used to treat stomach and liver cancers.

Methods

We retrospectively identified the advanced neuroendocrine carcinoma patients in Bayi Hospital Affiliated Nanjing University of Chinese Medicine Nanjing who received apatinib therapy for second line or post- second line from August 2015 to January 2018.The overall survival (OS) was defined as the duration between the date of treatment initiation to the date of death or last follow-up, with patients alive at last follow up censored on that date. We defined progression-free survival (PFS) from the date of first recurrence to the date of second recurrence or death, with patients censored on the date of last follow-up, if the patient was without recurrence on that date. Survival data was calculated by Kaplan-Meier method. Adverse events were evaluated based on the National Cancer Institute Common Toxicity Criteria (NCICTC) version 4.0. Radiographic assessment was made by oncologist and radiologists according to RECIST1.1.

Results

Ten neuroendocrine carcinoma patients were identified who had received apatinib treatment. The response rate (RR) and disease control rate (DCR) were 10% and 60%, respectively. Median PFS was 8.5 months, and medianOS) was 12.1 months. The main side effects were proteinuria (30%), oral mucositis (30%), hand-foot syndrome (30%), and bone marrow suppression (20%).

Conclusions

Above all, apatinib may provide a novel drug for the treatment of advanced neuroendocrine carcinoma patients, and also we should pay special attention to the side effects of apatinb. Meanwhile, further studies are required on the use of apatinib in neuroendocrine carcinoma in order to guide the clinical practice.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.